Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gensight BiologicsGSGTF 3-Year EBITDA Growth Rate is 51.50% as of Dec. 2025, which is 254% above its 10-year median of 14.55. The stock has 8 warning signs investors should review. Among 1,135 Biotechnology companies, Gensight Biologics ranks better than 86.52% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 51.50% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 41.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 23.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Gensight Biologics was 51.50% per year. The lowest was -86.90% per year. And the median was 14.55% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Gensight Biologics 3-Year EBITDA Growth Rate Related Terms
GSGTF vs VRTX, REGN, RVMD: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Gensight Biologics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gensight Biologics 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gensight Biologics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Gensight Biologics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 51.50% mean?
Gensight Biologics (GSGTF) has a 3-Year EBITDA Growth Rate of 51.50% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gensight Biologics and its competitors. This is 254% above median its historical median of 14.55. According to the industry distribution chart, Gensight Biologics ranks #153 out of 1135 companies in the Biotechnology industry, placing it in the top 13.5%.
Is Gensight Biologics' 3-Year EBITDA Growth Rate too high?
Gensight Biologics' current 3-Year EBITDA Growth Rate of 51.50% is 254% above median its 10-year median of 14.55. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.80. Gensight Biologics' value of 51.50% is 248% above this industry median. Based on the distribution chart, Gensight Biologics ranks #153 out of 1135 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does Gensight Biologics' 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Gensight Biologics ranks #153 out of 1135 companies for 3-Year EBITDA Growth Rate. This places Gensight Biologics in the top 14% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.80. Gensight Biologics' value of 51.50% is 248% above this benchmark. While the company's 10-year median is 14.55 vs. the industry median of 14.80, Gensight Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.80, based on 1,135 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gensight Biologics's current 3-Year EBITDA Growth Rate of 51.50% is 248% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Gensight Biologics and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gensight Biologics's current 3-Year EBITDA Growth Rate is 51.50%, which is 254% above median its own 10-year median of 14.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gensight Biologics stock overvalued right now?
Based on GuruFocus' analysis, Gensight Biologics (GSGTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.04, compared to a current price of $0.09 — trading 125% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 51.50%, which is 254% above median its 10-year median of 14.55 and 248% above the Biotechnology industry median of 14.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Gensight Biologics (GSGTF), the current 3-Year EBITDA Growth Rate is 51.50% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gensight Biologics SA is a clinical-stage biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GSGTF has been successfully added to your 
